Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Inventory (2016 - 2025)

Haemonetics has reported Inventory over the past 16 years, most recently at $321.2 million for Q4 2025.

  • For Q4 2025, Inventory rose 1316.61% year-over-year to $321.2 million; the TTM value through Dec 2025 reached $321.2 million, up 1316.61%, while the annual FY2025 figure was $365.1 million, 15.11% up from the prior year.
  • Inventory for Q4 2025 was $321.2 million at Haemonetics, down from $336.2 million in the prior quarter.
  • Over five years, Inventory peaked at $382.1 million in Q3 2024 and troughed at -$26.4 million in Q4 2024.
  • A 5-year average of $296.4 million and a median of $311.5 million in 2022 define the central range for Inventory.
  • Biggest five-year swings in Inventory: crashed 108.68% in 2024 and later surged 1316.61% in 2025.
  • Year by year, Inventory stood at $322.7 million in 2021, then dropped by 20.74% to $255.8 million in 2022, then rose by 18.87% to $304.0 million in 2023, then crashed by 108.68% to -$26.4 million in 2024, then surged by 1316.61% to $321.2 million in 2025.
  • Business Quant data shows Inventory for HAE at $321.2 million in Q4 2025, $336.2 million in Q3 2025, and $360.5 million in Q2 2025.